Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021)

Elicio Therapeutics filings provide 2 years of Cost of Revenue readings, the most recent being $433000.0 for Q4 2021.

  • On a quarterly basis, Cost of Revenue rose 243.65% to $433000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $433000.0, a 63.61% decrease, with the full-year FY2021 number at $433000.0, down 63.61% from a year prior.
  • Cost of Revenue hit $433000.0 in Q4 2021 for Elicio Therapeutics, up from $126000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $433000.0 in Q4 2021 to a low of $126000.0 in Q4 2020.